GlassScriptPhysician profile
Phoebe Oakes
NPI 1801096664
$3,131.61
in general payments reported to CMS, 2019-2025
29 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.53 · 2023: $840 · 2024: $1,067 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,051.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.41 | 2022-2025 | |
| Pfizer INC. | $388.95 | 2023-2025 | |
| Esperion Therapeutics, INC. | $357.94 | 2023-2025 | Nexletol |
| Lilly USA, LLC | $255.06 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $252.72 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $248.11 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $202.04 | 2023-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $166.93 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $113.29 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $108.46 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $106.06 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $48.34 | 2022-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $47.92 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.20 | 2025 | Caplyta |
| Exeltis, USA INC. | $41.35 | 2024 | Slynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $28.34 | 2023 | Rexulti |
| Eisai INC. | $24.32 | 2024 | |
| Organon LLC | $20.16 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2025 | |
| Boston Scientific Corporation | $17.77 | 2025 | Watchman Flx |
| Abiomed | $17.77 | 2023 | Impella |
| Abbott Laboratories | $17.18 | 2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $15.90 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $14.74 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $13.53 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.41 | 2024 | Zoryve |
| Azurity Pharmaceuticals, INC. | $12.97 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phoebe Oakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.